Navigation Links
eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
Date:5/20/2008

PHILADELPHIA, May 20 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that Dr. Michael J. McKelvey, the Company's President and Chief Executive Officer, and Richard Baron, the Company's Chief Financial Officer, are scheduled to present at the FBR 12th Annual Spring Investor Conference at 9:00 a.m. Eastern on May 28, 2008 at the Grand Hyatt Hotel in New York, New York.

Interested parties may access the presentation by visiting the Company's corporate website at http://www.ert.com or (Due to the length of the URL please copy and paste into your browser.) http://guest.cvent.com/EVENTS/Info/Custom.aspx?cid=20&e=53124f2c-1b1a-40ac- bb48-63c7d3febed2. The webcast will be available via replay for 90 days.

About eResearchTechnology:

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Forward-looking Statements:

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2008 financial guidance, involve a number of risks and uncertainties such as the company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Report on Form 10-K and 10Q filed with the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
2. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
3. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
4. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
5. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
6. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
7. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
8. eResearchTechnology Reports First Quarter 2008 Results
9. eResearchTechnology Announces Resignation of its CFO
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... HATFIELD, Pa. , April 26, 2017 /PRNewswire/ ... drug delivery platform, has signed a collaborative and ... through Dr. Silvia Muro . The overall ... pharmacokinetics and pharmacodynamics of various 3DNA designs and ... aims involve targeting diseases of the vasculature as ...
(Date:4/25/2017)... PROVIDENCE, R.I. , April 25, 2017 /PRNewswire/ ... EpiVax, Inc. ("EpiVax") has licensed its novel immune-modulating technology ... in autoimmune disease and allergy. Tregitopes, ... discovered in human immunoglobulin by EpiVax CEO ... Martin. Similar to intravenous immunoglobulin G, an autoimmune ...
(Date:4/24/2017)... Linda, Ca (PRWEB) , ... April 24, 2017 ... ... protect proteins from thermal denaturation in a cellular milieu; however, the broad application ... a lack of simple platforms with sensitive quantitative readouts. Cell-based thermal stabilization assays ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... and Webster Bank, today announced first round funding to three startups through the ... early-stage financial support to new business startups affiliated with UConn. , The UConn ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):